FEMTRACE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FEMTRACE (FEMTRACE).
Estrogen receptor agonist; binds to estrogen receptors, modulating gene transcription and cellular proliferation in target tissues.
| Metabolism | Hepatic metabolism primarily via CYP3A4; also undergoes glucuronidation and sulfation. Metabolites include estrone and estriol. |
| Excretion | Primarily renal; ~40% as unchanged drug and glucuronide conjugates. Biliary/fecal elimination is minor (~10-15%). |
| Half-life | Terminal elimination half-life is approximately 12-14 hours, supporting once-daily dosing in clinical use. |
| Protein binding | Approximately 95% bound, primarily to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Vd approximately 0.8-1.2 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Oral: ~30-40% due to first-pass metabolism. Comparative routes (e.g., transdermal) are not applicable as this drug is oral only. |
| Onset of Action | Oral: 30-60 minutes for symptom relief (e.g., hot flashes). |
| Duration of Action | Oral: 24 hours, with steady-state achieved after 5-7 days. |
| Molecular Weight | 272.38 |
1 to 2 mg orally once daily; for testosterone replacement in adult males, 2 to 4 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment is recommended; use with caution in severe renal impairment. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, use with caution and consider reduced doses. |
| Pediatric use | Not recommended for use in pediatric patients. |
| Geriatric use | Use with caution; consider lower starting doses due to increased risk of adverse effects such as fluid retention and cardiovascular events. |
| 1st trimester | Avoid. Estradiol is teratogenic; risk of fetal malformations including cardiovascular and limb defects. |
| 2nd trimester | Avoid. Continued risk of adverse effects on fetal development and potential feminization of male fetuses. |
| 3rd trimester | Avoid. Possible adverse effects on fetal genitalia and risk of premature closure of epiphyses. |
Clinical note
Comprehensive clinical and safety monograph for FEMTRACE (FEMTRACE).
| Placental transfer | Estradiol crosses the placenta readily, with fetal concentrations approximately 50% of maternal levels. |
| Breastfeeding | Estradiol is excreted into breast milk in small amounts. May reduce milk production and affect infant development. Use only if clearly needed and with monitoring of infant growth. |
■ FDA Black Box Warning
Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus. Unopposed estrogen use is associated with an increased risk of endometrial hyperplasia and carcinoma. Concomitant progestin therapy is recommended.
| Serious Effects |
Undiagnosed abnormal genital bleedingKnown or suspected pregnancyBreast cancer (known, suspected, or history)Estrogen-dependent neoplasiaActive deep vein thrombosis or pulmonary embolismActive or recent arterial thromboembolic disease (e.g., stroke, MI)Liver disease or impaired liver functionHypersensitivity to estradiol or any component
| Precautions | Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism), breast cancer, dementia (increased risk in women aged ≥65 years), gallbladder disease, hypertriglyceridemia, hereditary angioedema, and exacerbation of endometriosis. |
| Food/Dietary | Grapefruit juice may increase estradiol levels by inhibiting CYP3A4; avoid concurrent consumption. High-fat meals may enhance absorption; take consistently with or without food. Calcium supplements may interfere with absorption; if used, consider spacing doses. St. John's wort may reduce estradiol efficacy; avoid concurrent use. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | FEMTRACE (estradiol) is contraindicated in pregnancy. Use in first trimester associated with congenital anomalies (cardiovascular, limb defects). Second and third trimester fetal risks include urogenital abnormalities, neurodevelopmental effects. No adequate human studies; animal studies show teratogenicity. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, liver function, and signs of thromboembolism. Fetal monitoring not indicated if appropriate contraception used; if exposure occurs, consider fetal echocardiography and detailed anatomy ultrasound. |
| Fertility Effects | Estradiol suppresses gonadotropins, inhibiting ovulation; may impair fertility during use. Effects are reversible upon discontinuation. |
| Clinical Pearls | Femtrace (estradiol acetate) is a prodrug of 17β-estradiol, providing higher oral bioavailability than micronized estradiol. Dosing is 1.8 mg daily; lower starting doses are insufficient for symptom control. Monitor endometrial thickness in women with an intact uterus; consider adding a progestin if indicated. Avoid use in pregnancy; contraindicated in breast cancer, active thromboembolic disease, and hepatic impairment. Evaluate cardiovascular risk before prescribing; estrogen therapy may increase risk of stroke and DVT. |
| Patient Advice | Take the tablet at the same time each day with food to reduce gastrointestinal upset. · Do not use if you are pregnant, breastfeeding, or have a history of blood clots, certain cancers, or liver disease. · Report symptoms of blood clots such as leg pain/swelling, sudden shortness of breath, or chest pain. · Undergo regular breast exams and mammograms as recommended; inform all healthcare providers of your estrogen use. · If you have a uterus, discuss adding a progestin to prevent endometrial cancer. · Common side effects include nausea, breast tenderness, headache, and bloating; these often subside with continued use. |